Literature DB >> 31034749

Tau tubulin kinases in proteinopathy.

Laura M Taylor1, Pamela J McMillan2, Brian C Kraemer1,2,3,4, Nicole F Liachko1,3.   

Abstract

A number of neurodegenerative diseases are characterized by deposition of abnormally phosphorylated tau or TDP-43 in disease-affected neurons. These diseases include Alzheimer's disease, frontotemporal lobar degeneration, and amyotrophic lateral sclerosis. No disease-modifying therapeutics is available to treat these disorders, and we have a limited understanding of the cellular and molecular factors integral to disease initiation or progression. Phosphorylated tau and TDP-43 are important markers of pathology in dementia disorders and directly contribute to tau- and TDP-43-related neurotoxicity and neurodegeneration. Here, we review the scope of tau and TDP-43 phosphorylation in neurodegenerative disease and discuss recent work demonstrating the kinases TTBK1 and TTBK2 phosphorylate both tau and TDP-43, promoting neurodegeneration. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  zzm321990ALSzzm321990; zzm321990CBDzzm321990; zzm321990FTLDzzm321990; zzm321990PSPzzm321990; Alzheimer's disease; Pick's disease; TDP-43; TTBK1; TTBK2; phosphorylation; tau; tauopathy

Mesh:

Substances:

Year:  2019        PMID: 31034749      PMCID: PMC6936727          DOI: 10.1111/febs.14866

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  129 in total

1.  Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.

Authors:  Shinji Higashi; Eizo Iseki; Ryoko Yamamoto; Michiko Minegishi; Hiroaki Hino; Koshiro Fujisawa; Takashi Togo; Omi Katsuse; Hirotake Uchikado; Yoshiko Furukawa; Kenji Kosaka; Heii Arai
Journal:  Brain Res       Date:  2007-10-25       Impact factor: 3.252

2.  Altered microtubule organization in small-calibre axons of mice lacking tau protein.

Authors:  A Harada; K Oguchi; S Okabe; J Kuno; S Terada; T Ohshima; R Sato-Yoshitake; Y Takei; T Noda; N Hirokawa
Journal:  Nature       Date:  1994-06-09       Impact factor: 49.962

Review 3.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

4.  Tau reduction prevents Abeta-induced defects in axonal transport.

Authors:  Keith A Vossel; Kai Zhang; Jens Brodbeck; Aaron C Daub; Punita Sharma; Steven Finkbeiner; Bianxiao Cui; Lennart Mucke
Journal:  Science       Date:  2010-09-09       Impact factor: 47.728

5.  Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Masato Hasegawa; Tetsuaki Arai; Takashi Nonaka; Fuyuki Kametani; Mari Yoshida; Yoshio Hashizume; Thomas G Beach; Emanuele Buratti; Francisco Baralle; Mitsuya Morita; Imaharu Nakano; Tatsuro Oda; Kuniaki Tsuchiya; Haruhiko Akiyama
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

6.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

7.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

8.  Characterization of tau oligomeric seeds in progressive supranuclear palsy.

Authors:  Julia E Gerson; Urmi Sengupta; Cristian A Lasagna-Reeves; Marcos J Guerrero-Muñoz; Juan Troncoso; Rakez Kayed
Journal:  Acta Neuropathol Commun       Date:  2014-06-14       Impact factor: 7.801

9.  Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration.

Authors:  Laura M Taylor; Pamela J McMillan; Nicole F Liachko; Timothy J Strovas; Bernardino Ghetti; Thomas D Bird; C Dirk Keene; Brian C Kraemer
Journal:  Mol Neurodegener       Date:  2018-02-06       Impact factor: 14.195

10.  Spinocerebellar ataxia type 11-associated alleles of Ttbk2 dominantly interfere with ciliogenesis and cilium stability.

Authors:  Emily Bowie; Ryan Norris; Kathryn V Anderson; Sarah C Goetz
Journal:  PLoS Genet       Date:  2018-12-10       Impact factor: 5.917

View more
  6 in total

1.  Knockdown of circ-TTBK2 Inhibits Glioma Progression by Regulating miR-1283 and CHD1.

Authors:  Chengchen Han; Shuwei Wang; Hongwei Wang; Jianning Zhang
Journal:  Cancer Manag Res       Date:  2020-10-13       Impact factor: 3.989

2.  In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism.

Authors:  Nesli-Ece Sen; Aleksandar Arsovic; David Meierhofer; Susanne Brodesser; Carola Oberschmidt; Júlia Canet-Pons; Zeynep-Ece Kaya; Melanie-Vanessa Halbach; Suzana Gispert; Konrad Sandhoff; Georg Auburger
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923

Review 3.  Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration.

Authors:  Marcello Giunta; Eino Solje; Fabrizio Gardoni; Barbara Borroni; Alberto Benussi
Journal:  J Exp Pharmacol       Date:  2021-03-24

Review 4.  Alterations in Tau Metabolism in ALS and ALS-FTSD.

Authors:  Michael J Strong; Neil S Donison; Kathryn Volkening
Journal:  Front Neurol       Date:  2020-11-23       Impact factor: 4.003

5.  Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer's Disease.

Authors:  Farida Dakterzada; Iván David Benítez; Adriano Targa; Albert Lladó; Gerard Torres; Leila Romero; David de Gonzalo-Calvo; Anna Moncusí-Moix; Adria Tort-Merino; Raquel Huerto; Manuel Sánchez-de-la-Torre; Ferran Barbé; Gerard Piñol-Ripoll
Journal:  Front Aging Neurosci       Date:  2021-08-23       Impact factor: 5.750

6.  Synergistic toxicity between tau and amyloid drives neuronal dysfunction and neurodegeneration in transgenic C. elegans.

Authors:  Sarah J Benbow; Timothy J Strovas; Martin Darvas; Aleen Saxton; Brian C Kraemer
Journal:  Hum Mol Genet       Date:  2020-02-01       Impact factor: 6.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.